Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial
Titel:
Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial
Auteur:
Nguyen, Thuy P. Do, Quyet Phan, Lan T. Dinh, Duc V. Khong, Hiep Hoang, Luong V. Nguyen, Thuong V. Pham, Hung N. Chu, Men V. Nguyen, Toan T. Pham, Quang D. Le, Tri M. Trang, Tuyen N.T. Dinh, Thanh T. Vo, Thuong V. Vu, Thao T. Nguyen, Quynh B.P. Phan, Vuong T. Nguyen, Luong V. Nguyen, Giang T. Tran, Phong M. Nghiem, Thuan D. Tran, Tien V. Nguyen, Tien G. Tran, Tuynh Q. Nguyen, Linh T. Do, Anh T. Nguyen, Dung D. Ho, Son A. Nguyen, Viet T. Pham, Dung T. Tran, Hieu B. Vu, Son T. Hoang, Su X. Do, Trung M. Ngoc, Hoan Vu Nguyen, Xuan T. Le, Giang Q. Tran, Ton Cao, Thang M. Dao, Huy M. Nguyen, Thao T.T. Doan, Uyen Y Le, Vy T.T. Tran, Linh P. Nguyen, Ngoc M. Nguyen, Ngoc T. Pham, Hang T.T. Nguyen, Quan H. Nguyen, Hieu T. Nguyen, Hang L.K. Tran, Vinh T. Tran, Mai T.N. Nguyen, Truc T.T. Ha, Phat T. Huynh, Hieu T. Nguyen, Khanh D. Thuan, Ung T. Doan, Chung C. Do, Si M.